US company aims to slash cost of cancer drugs priced at more than $1 million

Expensive CAR T-cell immunotherapy could plummet in price to bring life-saving care to the masses

Novel CAR T-cell therapies offering bespoke treatments are some of the most expensive to produce and deliver, making them out of reach for the majority of patients. AFP

Cancer drugs costing more than $1 million could be drastically reduced in price by changes to the way immunotherapies are produced, opening up new opportunities for life-saving care.

Novel CAR T-cell therapies offering bespoke treatments are some of the most expensive to produce and deliver, making them out of reach the majority of patients.

The basic cost to deliver the therapy is at least $350,000, with additional licensing fees and other hospital expenses often pushing prices beyond the $1m mark.

Chimeric antigen receptor (CAR) T-cell therapy is used to treat some blood cancers, and is created by scientists to suit a patient’s genetics.

T-cells are collected from a patient, then re-engineered in the lab and delivered to the patient to hunt down and destroy cancerous cells.

But thanks to changes in manufacturing processes, hospitals around the world are beginning to produce their own CAR T-cell therapies locally, drastically cutting costs.

Caring Cross, a US-based non-profit organisation, aims to make gene therapy accessible and affordable worldwide, by decentralising manufacturing and opening up a new avenue of cancer care for all patients.

Cancer care boost

Dr Boro Dropulic, executive director of Caring Cross, said a global strategy could reshape healthcare and provide life-saving treatments for those who need them most.

“There are a number of ways the cost can be reduced, mainly by reducing the cost of materials used in the process,” Dr Dropulic told The National.

“The single largest cost is the vector used to deliver the therapeutic genes into cells. We are addressing this issue by establishing a public benefit corporation called Vector BioMed, which manufactures GMP Lentiviral vectors at about half the price of other manufacturers.”

The shipping of cells from hospitals to a large single central manufacturing facility and back is expensive to establish and maintain, he added.

“It is very costly when the number of products produced from such a facility does not reach capacity, which is generally the case. By bringing manufacturing of cells to the place where patients come for care, we can reduce the cost to a tenth of the current cost when coupled with simple and efficient manufacturing processes and materials,” Dr Dropulic added.

Local manufacturing

Caring Cross aims to bring manufacturing sites for personalised therapies to local hospitals around the world, improving access to the ground-breaking science. By developing low-cost CAR T-cell manufacturing processes, low and middle income countries such as Brazil can independently manufacture CAR T-cells and reduce dependency on expensive commercial products.

The approach bridges the healthcare gap, making advanced treatments more accessible to families facing financial barriers and promoting healthcare equity. Benefits of decentralised manufacturing are already being seen in Spain, where costs have plummeted to below $100,000, and in India where therapy costs have fallen to as low as $35,000.

Dr Dropulic said prefabricated modular ‘clean rooms’ are manufactured and deployed fully equipped for CAR T-cell manufacture anywhere in the world.

“The model is particularly suited for cellular gene therapies, which is our focus,” he said. “If this model works in low to middle income nations, it can definitely work in the UAE and similar countries.”

An estimated 20 million new cancer cases were reported worldwide in 2022, resulting in nearly 10 million deaths. For the millions affected, life-saving treatments like CAR T-cell therapy are far out of reach.

Doctors turn to the therapy when other treatments have failed, or a patient’s blood cancer has returned.

That comes at a cost with patients in the UAE often referred overseas for treatments.

“CAR T-cell has transformed the way we think about and see cancers, and there are multiple indications now approved,” said Dr Humaid Al Shamsi, director of medical oncology services at Burjeel Medical City.

“There is a huge interest to bring CAR T-cell from haematology, into other forms of cancers as it has transformed the way we treat blood cancers. For the solid tumours like GI cancer, lung cancer, breast cancer, it's still not quite there yet.

“There are many studies and trials happening right now, but currently it's only approved for blood cancer.”

Therapies are expensive due to the huge investment required for research and development.

Overseas care

Dr Al Shamsi said about 15 Burjeel Medical City patients had been referred for expensive CAR T-Cell therapies, with the US and Singapore the most common destinations.

High costs remained a prohibitive factor in bringing therapies to the UAE, but that could change.

“To bring these drugs from preclinical studies to advanced stages can cost billions,” said Dr Al Shamsi.

“Licensing fees are also significant, exceeding Dh50 million. To get a return, they [pharmaceutical companies] have to charge more than average to recover these costs.

“It’s important to understand this is a personalised treatment, as we have to perform processes in a special way to develop CAR T-cells for each patient, which takes a lot of effort.

“The infrastructure itself is also very costly to build. We can cut this down by making drugs more accessible, with more factories and more manpower to handle this, as the time to collect the CAR T-Cell can take around 35 days.”

In April, the UAE’s Friends of Cancer Patients charity covered some of the costs of CAR T-Cell therapy for a 46-year-old Omani man who lived in Ras Al Khaimah.

The immunotherapy cost more than Dh1 million, with some of those costs paid by the charity.

The man was successfully treated for lymphoma at the Yas Clinic in Khalifa City.

In the first half of 2024, FoCP supported 96 patients, including six children, with Dh4.3m in care fees.

Cancer is an expensive disease to treat, with some of the most effective immunotherapies out of financial reach for many.

Charity support

In 2023 the charity supported the care of 323 cancer patients with Dh7.2 million of funding to treat 55 different cancers.

“We believe every individual, regardless of their financial situation, deserves equal access to quality cancer care and support,” said Aisha Al Mulla, director of Friends of Cancer Patients.

“The financial burden of cancer can be overwhelming, but we are dedicated to alleviating this stress through our comprehensive support programmes.”

In the US, approximately 1.8 million new cancer cases are diagnosed annually, leading to an estimated $5.6 billion in out-of-pocket expenses for patients and their families.

Meanwhile in the UAE, the year 2022 saw 5,526 new cancer diagnoses, and 2,283 deaths.

“Our mission is to ensure that no one faces this battle alone,” said Ms Al Mulla.

“By offering moral and financial support, we aim to alleviate the stress associated with treatment costs and empower patients to focus on their recovery, nurturing an environment where hope prevails.”